Xarelto
E49852
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
Statements (57)
| Predicate | Object |
|---|---|
| instanceOf |
anticoagulant
→
direct oral anticoagulant → factor Xa inhibitor → pharmaceutical drug → |
| hasActiveIngredient |
rivaroxaban
→
|
| hasAntidote |
andexanet alfa
→
|
| hasATCCode |
B01AF01
→
|
| hasBioavailability |
high oral bioavailability at lower doses
→
|
| hasBlackBoxWarning |
increased risk of thrombotic events after premature discontinuation
→
risk of spinal or epidural hematoma with neuraxial anesthesia or spinal puncture → |
| hasCommonAdverseEffect |
anemia
→
bleeding → dizziness → nausea → |
| hasContraindication |
active pathological bleeding
→
severe hypersensitivity to rivaroxaban → significant hepatic disease associated with coagulopathy → |
| hasDosingFrequency |
once daily for many indications
→
twice daily for some initial treatment regimens → |
| hasDrugClass |
antithrombotic agent
→
blood thinner → |
| hasGenericName |
rivaroxaban
→
|
| hasHalfLife |
approximately 11 to 13 hours in elderly subjects
→
approximately 5 to 9 hours in healthy young subjects → |
| hasIndication |
prevention of stroke in nonvalvular atrial fibrillation
→
prophylaxis of venous thromboembolism after hip replacement surgery → prophylaxis of venous thromboembolism after knee replacement surgery → reduction in the risk of recurrence of DVT and PE → reduction of risk of major cardiovascular events in patients with chronic coronary artery disease → reduction of risk of major cardiovascular events in patients with peripheral artery disease → thromboprophylaxis in acutely ill medical patients at risk for thromboembolic complications → treatment of deep vein thrombosis → treatment of pulmonary embolism → treatment of venous thromboembolism in pediatric patients → |
| hasInitialFDAApprovalYear |
2011
→
|
| hasMechanismOfAction |
decreases thrombin generation
→
reduces fibrin clot formation → selective inhibition of factor Xa → |
| hasPregnancyCategory |
may cause fetal risk; use only if potential benefit justifies potential risk
→
|
| hasProteinBinding |
high plasma protein binding
→
|
| hasSeriousAdverseEffect |
gastrointestinal bleeding
→
intracranial hemorrhage → major bleeding → |
| isComparedWith |
apixaban
→
dabigatran → warfarin → |
| isCoPromotedBy |
Janssen Pharmaceuticals
→
|
| isDosageForm |
film-coated tablet
→
oral suspension → |
| isManufacturedBy |
Bayer
→
|
| isMetabolizedBy |
CYP2J2
→
CYP3A4 → |
| isRouteOfAdministration |
oral
→
|
| isSubstrateOf |
BCRP
→
P-glycoprotein → |
| isTakenWithFood |
recommended for 15 mg and 20 mg doses
→
|
| wasApprovedBy |
U.S. Food and Drug Administration
→
|
Referenced by (1)
| Subject (surface form when different) | Predicate |
|---|---|
|
Johnson & Johnson
→
|
notableProduct |